No quarterly revenue total was found in OBSIDIAN THERAPEUTICS, INC.'s SEC filings.
Obsidian Therapeutics, Inc. (OBX) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$0
Operating cash flow
$0
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
61.77M
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- OBX (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 2130606
- Former names
- Gazelle Parent, Inc. (until Aug 3, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
|---|---|
| Net income | $0 |
| Operating cash flow | $0 |
| Total assets | $0 |
| Stockholders' equity | $0 |
| Cash and investments | $0 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K/A | Amended current report | Aug 14, 2026 | Jul 31, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Results of operations, Unregistered share sale, Change to shareholder rights, Auditor change, Change in control, Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure
|
Aug 3, 2026 | Jul 31, 2026 |
All 35 Obsidian Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.